AtriCure, Inc. (ATRC) stock
ATRCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30893% above fair value
$55.02−0.29 (-0.52%)
Close on Nov 17, 2026Market cap $2.80BP/E 262.0Yield –
AtriCure r&d expenses
Research and development expenses are spending on new products and technology.
AtriCure's R&D Expenses for the twelve months ending Jun 30, 2026 was $98.03M, down 9.0% year over year. For fiscal 2025 it was $99.21M, up 3.2% from the year before. Over ten years it grew 14.4% a year on average. The highest annual figure on record is $99.21M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $99.21M | +3.2% |
| FY2024 | Dec 31, 2024 | $96.18M | +30.1% |
| FY2023 | Dec 31, 2023 | $73.92M | +28.9% |
| FY2022 | Dec 31, 2022 | $57.34M | +18.2% |
| FY2021 | Dec 31, 2021 | $48.51M | +12.6% |
| FY2020 | Dec 31, 2020 | $43.07M | +4.5% |
| FY2019 | Dec 31, 2019 | $41.23M | +18.7% |
| FY2018 | Dec 31, 2018 | $34.72M | +1.7% |
| FY2017 | Dec 31, 2017 | $34.14M | -4.7% |
| FY2016 | Dec 31, 2016 | $35.82M | +39.2% |
| FY2015 | Dec 31, 2015 | $25.74M | +38.4% |
| FY2014 | Dec 31, 2014 | $18.60M | +38.4% |
| FY2013 | Dec 31, 2013 | $13.44M | +10.6% |
| FY2012 | Dec 31, 2012 | $12.15M | +2.4% |
| FY2011 | Dec 31, 2011 | $11.86M | +2.8% |
| FY2010 | Dec 31, 2010 | $11.53M | +1.0% |
| FY2009 | Dec 31, 2009 | $11.41M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $26.40M | -9.8% |
| Q1 FY2026 | Mar 31, 2026 | $24.24M | +7.6% |
| Q4 FY2025 | Dec 31, 2025 | $24.51M | -29.9% |
| Q3 FY2025 | Sep 30, 2025 | $22.89M | +9.2% |
| Q2 FY2025 | Jun 30, 2025 | $29.28M | +43.4% |
| Q1 FY2025 | Mar 31, 2025 | $22.53M | +13.5% |
| Q4 FY2024 | Dec 31, 2024 | $34.96M | +68.1% |
| Q3 FY2024 | Sep 30, 2024 | $20.96M | +3.0% |
| Q2 FY2024 | Jun 30, 2024 | $20.42M | +17.1% |
| Q1 FY2024 | Mar 31, 2024 | $19.85M | +29.5% |
| Q4 FY2023 | Dec 31, 2023 | $20.80M | +51.3% |
| Q3 FY2023 | Sep 30, 2023 | $20.35M | +34.2% |
| Q2 FY2023 | Jun 30, 2023 | $17.44M | +17.9% |
| Q1 FY2023 | Mar 31, 2023 | $15.33M | +12.5% |
| Q4 FY2022 | Dec 31, 2022 | $13.75M | -0.4% |
| Q3 FY2022 | Sep 30, 2022 | $15.17M | +34.4% |
| Q2 FY2022 | Jun 30, 2022 | $14.79M | +21.3% |
| Q1 FY2022 | Mar 31, 2022 | $13.63M | +21.5% |
| Q4 FY2021 | Dec 31, 2021 | $13.81M | +27.0% |
| Q3 FY2021 | Sep 30, 2021 | $11.28M | +6.7% |
| Q2 FY2021 | Jun 30, 2021 | $12.20M | +21.5% |
| Q1 FY2021 | Mar 31, 2021 | $11.22M | -3.2% |
| Q4 FY2020 | Dec 31, 2020 | $10.87M | -17.0% |
| Q3 FY2020 | Sep 30, 2020 | $10.58M | +4.2% |
| Q2 FY2020 | Jun 30, 2020 | $10.04M | +2.4% |
| Q1 FY2020 | Mar 31, 2020 | $11.59M | +41.7% |
| Q4 FY2019 | Dec 31, 2019 | $13.10M | +54.9% |
| Q3 FY2019 | Sep 30, 2019 | $10.15M | +18.7% |
| Q2 FY2019 | Jun 30, 2019 | $9.80M | +13.3% |
| Q1 FY2019 | Mar 31, 2019 | $8.18M | -9.7% |
| Q4 FY2018 | Dec 31, 2018 | $8.46M | +9.5% |
| Q3 FY2018 | Sep 30, 2018 | $8.56M | +7.4% |
| Q2 FY2018 | Jun 30, 2018 | $8.66M | -2.8% |
| Q1 FY2018 | Mar 31, 2018 | $9.06M | -5.2% |
| Q4 FY2017 | Dec 31, 2017 | $7.72M | -21.7% |
| Q3 FY2017 | Sep 30, 2017 | $7.97M | -3.7% |
| Q2 FY2017 | Jun 30, 2017 | $8.91M | – |
| Q1 FY2017 | Mar 31, 2017 | $9.55M | – |
| Q4 FY2016 | Dec 31, 2016 | $9.87M | – |
| Q3 FY2016 | Sep 30, 2016 | $8.27M | – |
See a number that looks wrong?